Eurazeo (FR:RF) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kurma Partners has announced the first close at EUR 140 million for its new Biofund IV, with a target of EUR 250 million and plans to make 16 to 20 new investments in innovative therapeutics. The fund, which has already completed three investments, continues Kurma’s strategy of collaborating with academic and industry professionals to foster Europe’s health innovation ecosystem. With cornerstone investments from Eurazeo, Bpifrance, and CSL, and following successful exits from the Biofund III portfolio, the new fund demonstrates investor confidence in Kurma’s approach to healthcare innovation.
For further insights into FR:RF stock, check out TipRanks’ Stock Analysis page.